Physics

Internal medicine

Propensity score matching

Hazard ratio

Diabetes mellitus

Incidence (geometry)

Optics

Endocrinology

Antibody

Immunology

Type 2 diabetes

Sulfonylurea

Bullous pemphigoid

Insulin

Pemphigoid

Linagliptin

Confidence interval

Medicine

JAMA Dermatology

Between 2012 and 2017, overall Medicare reimbursements for PDT services in metropolitan regions increased by $1 601 015 (average annual growth rate [AAGR], 4.0%), with 19 219 (AAGR, 4.7%) additional claims; overall Medicare reimbursements for PDT services in nonmetropolitan regions increased by $122 076 (AAGR, 3.2%), with 1625 (AAGR, 3.9%) additional claims (Table 2).As of 2017, metropolitan counties accounted for 90.9% of Medicare reimbursements for PDT claims ($9 260 322 of $10 184 822).Discussion | In this study, we present data characterizing the trends in use, accessibility, and cost of PDT among the US Medicare population.Despite the consistent growth in the number of dermatologists offering PDT, the density of dermatologists providing PDT in nonmetropolitan counties is less than half of that in metropolitan counties in the most recent study year; this difference has widened from 2012 to 2017.With the incidence of NMSCs rising, PDT could be important for prevention and treatment of some NMSCs while maintaining low costs. 2Strategies leading to more dermatologists offering PDT, such as recent increases to reimbursements, may, therefore, ultimately lower Medicare expenditures on skin cancer treatment, especially in nonmetropolitan areas, where our study suggests that PDT access is particularly lacking.This study has several limitations.Our use of Medicare claims data precludes evaluation of PDT use for patients with commercial insurance.Likewise, while PDT is generally performed in outpatient settings, exclusion of institutional providers (such as hospitals) in the data set may limit our ability to capture all PDT services.Conclusions | We found that the use of PDT increased in both metropolitan and nonmetropolitan regions from

Livedoid and Purpuric Skin Eruptions Associated With Coagulopathy in Severe COVID-19